Crinecerfont Lowers Elevated Hormone Markers in Adults with 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Richard J AuchusKyriakie SarafoglouPatricia Y FechnerMaria G VogiatziErik A ImelShanlee M DavisNagdeep GiriJulia SturgeonEiry RobertsJean L ChanRobert H FarberPublished in: The Journal of clinical endocrinology and metabolism (2021)
Crinecerfont treatment for 14 days lowered ACTH and afforded clinically meaningful reductions of elevated 17OHP, androstenedione, testosterone (women), or androstenedione/testosterone ratio (men) in adults with 21OHD. Longer-term studies are required to evaluate the effects of crinecerfont on clinical endpoints of disordered steroidogenesis and glucocorticoid exposure in patients with 21OHD.